Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merus NV

45.68
+0.17000.37%
Volume:611.41K
Turnover:27.67M
Market Cap:3.16B
PE:-13.62
High:46.01
Open:45.54
Low:44.80
Close:45.51
Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Arcellx Inc (ACLX)

TIPRANKS
·
09 Dec 2024

Truist Financial Sticks to Its Buy Rating for Merus (MRUS)

TIPRANKS
·
09 Dec 2024

Merus Price Target Maintained With a $85.00/Share by Needham

Dow Jones
·
09 Dec 2024

Merus Scores Its First FDA Approval For Lung Cancer Drug

Benzinga
·
06 Dec 2024

Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), Larimar Therapeutics (LRMR) and Merus (MRUS)

TIPRANKS
·
06 Dec 2024

Merus Is Maintained at Buy by Guggenheim

Dow Jones
·
05 Dec 2024

U.S.-Listed Shares of Netherlands-Based Merus up 1.6% After US FDA Approves Therapy to Treat Lung, Pancreatic Cancers

THOMSON REUTERS
·
05 Dec 2024

Merus Price Target Maintained With a $85.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Dec 2024

Merus Gets US FDA Approval for Bizengri in Advanced Pancreatic, Lung Cancers

MT Newswires Live
·
05 Dec 2024

Merus Gets FDA Approval for Bizengri Treatment

Dow Jones
·
05 Dec 2024

Merus gets FDA approval of BIZENGRI in NRG1+ Pancreatic Adenocarcinoma, NSCLC

TIPRANKS
·
05 Dec 2024

Merus’ zenocutuzumab-zbco granted accelerated approval by FDA

TIPRANKS
·
05 Dec 2024

Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC

Zacks
·
04 Dec 2024

Merus price target lowered to $109 from $111 at Guggenheim

TipRanks
·
04 Dec 2024

Merus Price Target Cut to $109.00/Share From $111.00 by Guggenheim

Dow Jones
·
04 Dec 2024

Merus Nv : Guggenheim Cuts Target Price to $109 From $111

THOMSON REUTERS
·
03 Dec 2024

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

Benzinga
·
03 Dec 2024

Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics

MT Newswires Live
·
02 Dec 2024

BUZZ-Merus gains on US commercialization agreement for cancer therapy

Reuters
·
02 Dec 2024

U.S.-Listed Shares of Merus Nv up About 5% Premarket After Commercialization Agreement for Co's Cancer Therapy

THOMSON REUTERS
·
02 Dec 2024